Will This Analyst Downgrade Hurt Theravance (THRX) Stock Today?

NEW YORK (TheStreet) -- Robert W. Baird downgraded Theravance  (THRX) to "neutral" from "outperform" and set a $21 price target. The firm noted Breo sales have been disappointing.

The stock was down 3.53% to $27.64 at 9:31 a.m. on Monday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

THRX Chart

THRX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Theravance (THRX) Highlighted As Weak On High Volume

Theravance (THRX) Flagged As Strong On High Volume

3 Sell-Rated Dividend Stocks: VER, BRS, THRX

The 10 Highest Dividend Health Care Stocks Are Not All Buys

5 Hated Stocks You Should Love This Earnings Season